Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. PATIENT SUMMARY: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions.
European urology focus. 2019 Jun 24 [Epub ahead of print]
Thomas Van den Broeck, Roderick C N van den Bergh, Erik Briers, Philip Cornford, Marcus Cumberbatch, Derya Tilki, Maria De Santis, Stefano Fanti, Nicola Fossati, Silke Gillessen, Jeremy P Grummet, Ann M Henry, Michael Lardas, Matthew Liew, Malcolm Mason, Lisa Moris, Ivo G Schoots, Theodorus van der Kwast, Henk van der Poel, Thomas Wiegel, Peter-Paul M Willemse, Olivier Rouvière, Thomas B Lam, Nicolas Mottet
Department of Urology, University Hospitals Leuven, Leuven, Belgium. Electronic address: ., St. Antonius Hospital, Utrecht, The Netherlands., Patient Advocate, Hasselt, Belgium., Royal Liverpool and Broadgreen Hospitals NHS Trust, Liverpool, UK., Academic Urology Unit, University of Sheffield, Sheffield, UK., Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Charité University Hospital, Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria., Nuclear Medicine Division, Policlinico S. Orsola, University of Bologna, Bologna, Italy., Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy., Division of Cancer Sciences, University of Manchester and The Christie, Manchester, UK; Department of Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland; University of Bern, Bern, Switzerland., Department of Surgery, Central Clinical School, Monash University, Melbourne, Australia., Leeds Cancer Centre, St. James’s University Hospital, University of Leeds, Leeds, UK., Department of Urology, Leto Hospital, Athens, Greece., Department of Urology, Wigan and Leigh NHS Foundation Trust, Wigan, UK., School of Medicine, Cardiff University, Cardiff, UK., Department of Urology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Molecular Endocrinology, KU Leuven, Leuven, Belgium., Department of Radiology & Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Department of Pathology, Erasmus Medical Centre, Rotterdam, The Netherlands., Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany., Department of Oncological Urology, University Medical Center, Utrecht Cancer Center, Utrecht, The Netherlands., Hospices Civils de Lyon, Radiology Department, Edouard Herriot Hospital, Lyon, France., Academic Urology Unit, University of Aberdeen, Aberdeen, UK; Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK., Department of Urology, University Hospital, St. Etienne, France.